Current status of DNA vaccines and their route of administration

被引:24
作者
Alpar, HO [1 ]
Bramwell, VW [1 ]
机构
[1] Univ London, Sch Pharm, Ctr Drug Delivery Res, London WC1N 1AX, England
来源
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 2002年 / 19卷 / 4-5期
关键词
DNA; vaccine; cancer; allergy; infectious diseases;
D O I
10.1615/CritRevTherDrugCarrierSyst.v19.i45.20
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review is aimed at bringing DNA vaccines into perspective with regard to other currently available vaccines and vaccine strategies in development. It is concluded that, encouragingly, DNA vaccines still offer significant potential, with more recent developments such as improved vectors and delivery systems likely to have an important impact; and in addition, the potential safety of DNA as a vaccine is becoming increasingly apparent. Strategies for oral delivery may be suitable for some applications, with all nonparenteral routes likely to require suitable carriers or adjuvants. The diversity of experimental data attests to the increasing interest in vaccination for the treatment and prevention of disease.
引用
收藏
页码:307 / 383
页数:77
相关论文
共 508 条
[1]  
ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969
[2]   MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines [J].
Acres, B ;
Apostolopoulos, V ;
Balloul, JM ;
Wreschner, D ;
Xing, PX ;
Ali-Hadji, D ;
Bizouarne, N ;
Kieny, MP ;
McKenzie, IFC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) :588-594
[3]   Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer [J].
Adams, M ;
Borysiewicz, L ;
Fiander, A ;
Man, S ;
Jasani, B ;
Navabi, H ;
Lipetz, C ;
Evans, AS ;
Mason, M .
VACCINE, 2001, 19 (17-19) :2549-2556
[4]   Noncytopathic Sindbis virus RNA vectors for heterologous gene expression [J].
Agapov, EV ;
Frolov, I ;
Lindenbach, BD ;
Pragai, BM ;
Schlesinger, S ;
Rice, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :12989-12994
[5]   DNA vaccines: Technology and application as anti-parasite and anti-microbial agents [J].
Alarcon, JB ;
Waine, GW ;
McManus, DP .
ADVANCES IN PARASITOLOGY, VOL 42, 1999, 42 :343-410
[6]   LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].
ALLISON, AC ;
GREGORIADIS, G .
NATURE, 1974, 252 (5480) :252-252
[7]   Nasal delivery of vaccines [J].
Almeida, AJ ;
Alpar, HO .
JOURNAL OF DRUG TARGETING, 1996, 3 (06) :455-467
[8]  
Almeida Antonio J., 1992, Biochemical Society Transactions, V20, p316S
[9]  
Alpar HO, 1996, IMMUNOLOGY, V89, pCC337
[10]   EFFECTIVENESS OF LIPOSOMES AS ADJUVANTS OF ORALLY AND NASALLY ADMINISTERED TETANUS TOXOID [J].
ALPAR, HO ;
BOWEN, JC ;
BROWN, MRW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 88 (1-3) :335-344